Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Molecular subtypes make difference on clinicopathologic features and response to chemotherapy
and targeted agents as well as prognosis. RAS mutation status, which accounting for
approximately 35% to 40% of colorectal cancer patients, is an important factor considered in
the standard of care for colorectal cancer. For RAS-mutated patients, no targeted driver gene
drugs have been approved, and their treatment is based on the anti-VEGF/VEGFR pathway, and
corresponding targeted drugs such as bevacizumab, aflibercept, and ramucirumab have also been
successfully marketed for the treatment of CRC.
For RAS mutant metastatic colorectal cancer, the commonly used first-line treatment regimen
is bevacizumab combined with chemotherapy, which is shown in previous studiesthat the PFS of
1st-line is about 10 months; the standard regimen of second-line treatment is FOLFIRI ±
bevacizumab, which is shown in previous study that the 2nd-line PFS is about 5 months with
ORR 4%. There are a lot of unmet medical needs to improve the clinical efficacy in
secondline-treatment of RAS-mutant patients.